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SUPPLEMENTARY NOTES
ABSTRACT
Diffuse Intrinsic Pontine Gliomas or DIPG, is a type of brain tumor that afflicts children and is the leading cause of death in pediatric brain tumor patients. One major obstacle to progress has been the lack of representative animal models that recapitulate the genetic alterations of the human disease in the appropriate cell-of-origin. Recent analysis of human DIPGs have unraveled the following key genetic alterations: K27M H3.3 or H3.1 mutations in 80% of tumors, p53 mutations in 75% of tumors, and focal amplification of components of the RTK/Ras/PI3K pathway in approximately 50% of tumors with 30% of tumors harboring amplification of PDGFRα. Using the RCAS/tv-a system, we have previously reported the development of a DIPG model by overexpression of PDGF-B in nestin progenitors of Ink4a-ARF deficient mice. Here we report the development of several improved DIPG models by overexpression of PDGF-B and Cre in nestin progenitors of conditional p53 deficient mice, conditional PTEN mice, and combined conditional p53 and PTEN mice. In addition we have also generated a new DIPG model by overexpression of PDGF-B and Cre in GFAP progenitors of conditional p53 mice. Lastly, to identify unique aspects of brainstem gliomagenesis we have compared the expression profile of the above described murine DIPG model to cortical gliomas induced by the same genetic alterations and unraveled that pax3 is a differentially expressed transcription factor that is upregulated in DIPGs and not in cortical gliomas.
SUBJECT TERMS
None provided. 
Introduction
Brain tumors are currently the leading cause of death for children with cancer. Diffuse Intrinsic Pontine Gliomas or DIPG, is a type of brain tumor that afflicts children and is the leading cause of death in pediatric brain tumor patients. One major obstacle to progress has been the lack of representative animal models that recapitulate the genetic alterations of the human disease in the appropriate cell-of-origin. Below is our current progress to date on the specific tasks as described in the Statement of Work. Overall, we are right on schedule with regards to our time-line. We also confirmed that this region-specific expression of pax3 is in the tumor compartment by using Olig2-GFP mice. By sorting DIPG tumor cells in the Olig2-GFP background for GFP, we sorted for the tumor cell compartment and observed that pax3 mRNA is mostly expressed in Olig-2 expressing tumor cells (data not shown). 
Task 1-Develop improved DIPG (Diffuse Intrinsic
Conclusion
Diffuse Intrinsic Pontine Glioma is an incurable tumor in 2012. This tumor is the leading cause of death in children with brain tumors. Our laboratory is one of few laboratories around the world that is studying this rare incurable tumor. Our approach is unique as we are using genetic engineered mouse modeling techniques to dissect the contribution of specific drivers to brainstem gliomagenesis, to identify the cell(s)-of-origin for DIPG formation, and to develop improved DIPG mouse models as preclinical tools. Our accomplishments so far are the development of improved DIPG mouse models, including a DIPG mouse model with a potential different cell-of-origin marker (GFAP as opposed to Nestin). In addition, we have identified pax3, a transcription factor that is significantly upregulated in our DIPG mouse model and not in a cortical glioma model that is driven by identical genetic alterations. As we start year 2 of the award, we will continue to improve our DIPG mouse models, move forward toward identifying a cell-of-origin for DIPG, and start preclinical testing with our DIPG mouse model. Several publications over the past few years have described the landscape of genetic alterations in this disease. As a result, we have requested to change two tasks to keep abreast with a significant discovery in the field -the identification of the K27M H3.3/H3.1 mutations in DIPG-since we initially submitted the application in 2010.
